Selective Targeting Reactive Oxygen Species for Age-related Macular Degeneration

Project Summary

Age-related macular degeneration (AMD) is an age related problem causing vision loss.  This disease is most commonly associated with the gradual buildup of free radicals (cellular waste products) within the central region of the retina, known as the macular.  By utilizing antioxidant nanoparticles to target and selectively eliminate free radical build up, we have created a potential solution to prevent AMD progression.  In this project, we will use our newly developed antioxidant nanoparticle formulations, in both cellular and murine AMD models, to test our hypothesis that the nanoparticle intervention has targeted therapeutics by reducing free radical-induced cell damage, while ensuring minimal side effects on the surrounding normal retinal cells.  The overall goal of this project is to combine the established outstanding treatments for AMD, while introducing more effective nano antioxidant treatments.  In doing this, we hope to complete the steps necessary to bring a safer and more effective nano antioxidant system into a clinical trial for both dry and wet AMD patients. We look to greatly benefit all AMD patients through our innovative treatment.